Calico Life Sciences LLC is a subsidiary of
Alphabet Inc. and with a focus on biotechnology their goal is to increase the understanding of the
biology that controls human
aging, attempting to devise interventions that may enable people to lead longer and healthier lives.
History
Calico, short for the California Life Company,[6][7] was announced on September 18, 2013, prior to
Google's restructuring and was co-founded by former
Genentech chairman and CEO
Arthur D. Levinson.[8] In Google's 2013 Founders Letter,
Larry Page described Calico as a company focused on "health, well-being, and
longevity."[9] It was incorporated into Alphabet with Google's other sister divisions in 2015.[10][11]
The Calico team has included a number of pioneering researchers in the field of ageing research, including members of the
National Academy of Sciences,
Cynthia Kenyon and Daniel E. Gottschling.[12] Some of the company’s earliest employees included the geneticist
David Botstein, and cancer drug developer Robert L. Cohen, MD.,[13]Eric Verdin, CEO of The Buck Institute for Research on Aging, served as a consultant to the Calico team.[14]
At the end of 2017 and the beginning of 2018, Calico lost two top scientists; in December 2017
Hal Barron, MD, its head of R&D, left for
GlaxoSmithKline, and in March 2018 chief computing officer
Daphne Koller, who was leading their
computational biology efforts, left to pursue a venture in applying machine learning techniques to drug design.[15][16][17]
Partnerships
In September 2014, Calico and
AbbVie announced an R&D collaboration focused on
aging and age-related diseases such as
neurodegeneration and
cancer.[18] Working together with AbbVie, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing capabilities. [19] AbbVie provides scientific and clinical development support and lends its expertise to commercialization activities.[20] To date, the companies have committed to invest more than $1 billion into the collaboration.[21]
In 2015, the
Broad Institute of MIT and Harvard announced a partnership with Calico to "advance research on age-related diseases and therapeutics",[22] a further partnership also was announced with the
Buck Institute for Research on Aging.[23] Also in 2015, Calico announced a partnership with
QB3 based on researching the biology of aging and identifying potential therapeutics for age-related diseases[24] and one with
AncestryDNA based on conducting research into the genetics of human lifespan.[25]
In October 2023, Nature, a weekly British scientific journal, published preclinical research findings that showed ABBV-CLS-484, a PTPN2/N1
phosphatase inhibitor being co-developed by AbbVie and Calico, provokes a potent dual response in cancer and immune cells.[26][27][28]
Reception
When Calico was formed, Google did not disclose many details, such as whether the company would focus on biology or information technology.[29] The company issued press releases about research partnerships, but not details regarding the results of its research or the specifics of what it was working on.[7][30] This led to frustration by researchers regarding Calico's secrecy[30] and questions as to whether Calico had produced any useful scientific advancements.[31] Calico said the business' purpose was to focus on long-term science not expected to garner results for 10 or more years, leaving nothing to report on in its first five years.[31]